Sirigiri Kusuma*
Student, Doctor of Pharmacy, Department of Pharmacy Practice, QIS College of Pharmacy, Ongole, Prakasam, Andhra Pradesh, India
*Corresponding Author: Sirigiri Kusuma, Student, Doctor of Pharmacy, Department of Pharmacy Practice, QIS College of Pharmacy, Ongole, Prakasam, Andhra Pradesh, India.
Received: June 27, 2020; Published: July 01, 2020
A bone disorder with low bone density, impaired bone architecture and low bone strength leading to predisposed fractures is termed as Osteoporosis [1]. Since the bone loss occurs without symptoms this is often called as the silent disease [2]. Due to reduced bone formation loss of bone mass occurs in either third or fourth decade in both men and women [1].
Citation: Sirigiri Kusuma. “An Editorial: Osteoporosis and Romosozumab".Acta Scientific Pharmacology 1.8 (2020): 01-02.
Copyright: © 2020 Sirigiri Kusuma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.